Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

New NHS treatment gives hope to thousands who suffer from common allergy

The first-of-its-kind tablet will offer relief from severe dust mite allergies

Jane Kirby
Wednesday 29 January 2025 19:01 EST
Comments
The first-of-its-kind tablet will offer relief from severe dust mite allergies
The first-of-its-kind tablet will offer relief from severe dust mite allergies (Getty Images)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

A new, first-of-its-kind tablet offering relief from severe dust mite allergies has been approved for NHS use, potentially benefiting thousands.

The National Institute for Health and Care Excellence (Nice) has given the green light to 12 SQ-HDM SLIT, also known as Acarizax, for individuals aged 12 to 65 suffering from persistent moderate to severe house dust mite allergic rhinitis.

This marks the first treatment Nice has recommended for this condition, estimated to affect around 13,000 people in England.

The tablet works by gradually desensitising the body to house dust mites. By administering a fixed daily dose of house dust mite allergy extract, the body builds resistance, reducing the severity of allergic reactions over time.

This is particularly beneficial for those whose symptoms don't adequately respond to traditional treatments like steroid nasal sprays and antihistamines.

The treatment is taken for three years at home to build up the bodyā€™s resistance.

A dust mite
A dust mite

Common symptoms of allergic rhinitis include sneezing, an itchy nose, a runny or blocked nose and itchy, red and watery eyes.

In severe cases it can be debilitating and cause facial swelling, fatigue and affect peopleā€™s sleep, Nice said.

Persistent allergy is when symptoms occur on four or more days a week for a month and have not been helped by standard treatments.

People will be eligible for the new pill after medics have looked at their medical history and if they test positive for house dust mite allergy through the allergy skin prick test or specific immunoglobulin E [IgE]) test.

Helen Knight, director of medicines evaluation at Nice, said: ā€œFor people with house dust mite allergic rhinitis that is not controlled by standard treatments, this new cost-effective drug will have a significant positive impact on their quality of life.

ā€œThis is a chronic, debilitating condition which can prevent people from going to their workplace or school.

ā€œThis medicine has been found to improve symptoms, helping people to live their lives and has potential to be truly life changing.ā€

Dr Helen Evans-Howells, a patient expert and a GP, said: ā€œThis drug could be life-changing for those affected by severe symptoms which include significant fatigue, congestion and facial swelling.

ā€œThe evidence clearly shows it offers an effective solution for those who have struggled with standard treatments.ā€

Amena Warner, head of clinical services at Allergy UK, said the decision was a ā€œlandmark stepā€.

ā€œMany endure years of misery; of nasal congestion, loss of smell and sneezing, impacting their sleep and daily living with little respite from symptoms.

ā€œThis can also affect mental wellbeing. With this treatment there is now hope for people who fit the criteria to be able to access this through the NHS.ā€

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in